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nonlinear PK, DDI related changes in clearance, and absolute bio-
availability/mass balance data.
Conclusion: This integrated study design is a highly efficient mecha-
nism for generating definitive intravenous pharmacokinetic, clear-
ance, absolute bioavailability, mass balance, and human metabolism 
data from a single radiolabeled clinical protocol.
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Introduction: In recent years, improvement efforts have been geared 
toward activating clinical research performed in Japan. However, 
objectives of clinical research and trials are often unclear to the 
general public, given the difficulty in obtaining appropriate infor-
mation. To gain access to appropriate information about clinical 
research and trials, the general public needs information tools that 
are easy to use, as well as a basic knowledge about clinical research 
and trials. Building an efficient and easy-to-use portal site for patients 
and citizens is a major component of the new “5-year Clinical Trial 
Activation Plan (2012).” The present study aimed to investigate the 
type of information required and the kind of portal site considered 
useful by the general public based on a questionnaire survey.
Patients (or Materials) and Methods: Subjects of this study included 
500 Internet users aged ≥ 20 years. We used an Internet research 
method. The period of internet research from December 10, 2012, 
to December 20, 2012.The survey questionnaire mainly consisted of 
the following 3 parts:
1.  What kind of information do you want to obtain from a “clini-
cal research (trials) information site”?
2.  Ideas and wishes helpful for improving the information site 
(free-style questions)
3.  What kind of tools do you find easy to use when accessing the 
information site?
This study was carried out as part of the study funded by Grant-
in-Aid for Scientific Research of Health, Labour and Welfare in 
2012 FY. The study protocol was approved by the Kitasato Institute 
Hospital Research Ethics Committee.
Results: 1. The clinical research information which they considered 
highly necessary were “purpose,” “method,” “risks by participat-
ing,” “compensation if there is a health hazard,” “inconvenience or 
danger,” “cost,” and “period.”
2. Survey results showed that a site that allows the user to quickly 
extract only what is relevant to him/her was desired (eg, “I can search 
if I put the name of disease and symptoms,” “I want to be able to 
search by region,””Iwant a visualfriendly site”), in addition to “ease 
of access,” “explicit basis of reliability,” and “use of plain vocabulary.”
3. More than 90% responded that they use a personal computer 
(PC) at home to access the Internet. Use of a smartphone was < 30%, 
with the percentage being higher in younger respondents than older 
respondents. While > 60% of people used a PC for a longer time 
period than they used a smartphone, people in their 20s and 30s 
used a smartphone longer. While use of the social networking site 
(SNS) has spread recently, as a whole, it remained at 9.8%, except 
in the 20s (30%).
Conclusion: While building a web portal as a means to provide 
appropriate information is necessary, it is also important to increase 
the basic knowledge of clinical research and trials in the general pub-
lic so that they can determine the appropriateness of the information 
available to them.
Disclosure of Interest: None declared.
PP169—PioGlitAzone in mild to moderAte 
ulCerAtive ColitiS: A PlACebo Controlled 
rAndomized triAl
B. Medhi1*; S. Kaur1; S.C. Sarangi1; A. Prakash1; U. Dutta2; and 
R. KOCHHAR2
1Department Of Pharmacology; and 2Department Of 
Gastroenterology, Postgraduate Institute Of Medical Education 
And Resaerch, Chandigarh, India
Introduction: The treatment modalities of ucerative colitis is an 
unmate need. The present study aims to evaluate efficacy of piogl-
itazone in mild to moderate ulcerative colitis patients compared with 
placebo. Previous studies were reportedly done on rosiglitazone, 
and this is foremost study to evaluate the efficacy of pioglitazone in 
ulcerative colitis patients.
Patients (or Materials) and Methods: Total 32 patients were seen 
in the study. It was a randomized, double-blind, placebo-controlled 
clinical trial compared the efficacy of pioglitazone 15 mg or placebo 
orally twice daily for 8 weeks in patients with mild to moderate active 
ulcerative colitis. The first group received 15-mg pioglitazone 2 times 
daily along with mesalamine. Second group received mesalamine plus 
similar looking placebo. The patients were followed up to 8 weeks, 
response to treatment was assessed clinically by Mayo clinical scor-
ing systems. Sigmoidoscopy was done at baseline and at 8 weeks of 
completion of treatment.
Results: Five patients were treated with pioglitazone and 4 patients were 
treated with placebo, completed therapy and achieved primary outcome. 
Gastrointestinal quality of life scores showed significant improvement 
in pioglitazone score compared with placebo group (0.03). Among the 
secondary efficacy end points, therapy with pioglitazone group lead to 
decrease in stool frequency, consistency, blood in stools, and abdominal 
pain. In placebo group the stool frequency decreased from (4.8 [3] to 
2 [1]) at the end of 8 weeks though the stool frequency was higher in 
placebo group initially. During the study, pioglitazone showed edema 
and weight gain and in placebo group, nausea, vomiting, abdominal 
pain, and diarrhea were most commonly observed.
Conclusion: The present double-blinded, placebo-controlled study 
with 8 weeks therapy of pioglitazone was not found superior to 
placebo for induction of clinical response in patients with ulcerative 
colitis.
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Introduction: While bariatric surgery (BS) to combat obesity con-
fers risks, it can also result in remission of diabetes mellitus (DM). 
Clinicians managing such patients should appreciate the relative and 
absolute extents of the latter effect. We therefore set out to derive 
unadjusted values for the relative chance (RC) and number needed 
to treat (NNT) for such an effect.
Patients (or Materials) and Methods: Two recently published, non-
blinded, randomized clinical trials compared DM remission rates 
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in severely obese diabetic patients having BS versus conventional/-
intensive antidiabetic therapy.1,2 Respectively, in these trials: patient 
numbers were 60 and 150, primary end points were 2-year HBA1C 
level ≤6.5% (with fasting glucose < 100 mg/dL and no anti-DM 
pharmacotherapy) and 1-year HBA1C levels ≤6%, and surgical 
interventions were gastric bypass and bilio-pancreatic diversion and 
gastric bypass and sleeve gastrectomy. As previously described,3 we 
calculated respective unadjusted RC (akin to relative risk), NNT, 
and 95% CI values.
Results: The patients in these trials did not suffer any serious compli-
cations from their BS. Respective RC, NNT, and corresponding (CI) 
values were 8.5 (2.0–36.4) and 1.33 (1.08–1.74) and 3.2 (1.2–8.4) 
and 3.68 (2.42–7.68).
Conclusion: In the short-term (1–2 years), BS was a highly effective 
means of eliminating DM in these patients. The perceived success rate 
depended on the precise criteria used to define diabetes and the type 
of BS, but due to small sample sizes apparent statistical significance 
cannot be discerned with confidence.
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Introduction: The problem of effective and rational treatment of no 
viral hepatitis is still actual. During several last years, the screening 
of the bioactivity of the list of semi-synthetic derivatives of alkaloid 
cytisine was held in our laboratories. The result was the synthesis 
of O,O dimethyl-N-cytinizylphosphate (cytisin amidophosphate). 
Hepatoprotective properties were noted on the several models of 
acute and chronic hepatitis. Purpose: to study the efficacy and safety 
of cytisin amidophosphate under the name of Cytaphat in patients 
with toxic hepatopathy.
Patients (or Materials) and Methods: A total of 142 patients (age, 
16–56) with the verified (by history, objective status, ultrasound, 
and according to biochemical tests) diagnosis of acute toxic hepatitis 
(poisoning with ethyl alcohol – 49; alcohol surrogates – 89; par-
acetamol – 3; reserpine – 1), who took treatment in the toxicologic 
department were included in the clinical research. The patients were 
randomly divided into 3 groups: 34 patients were taking Essentiale 
(200 mL of 5% glucose + 10 mL of Essentiale) IV once per day for 3 
days; 94 patients were taking Cytaphat (10 mg/kg + 200 mL of 5% 
glucose) IV once per day for 3 days; 14 patients were taking placebo 
(200 mL of 5% glucose) IV once per day for 3 days. The method of 
clinical trials was double-blind.
Results: Three days after the implementation of Essentiale or 
Cytaphat, all patients reported a significant (subjective opinion) 
recovery: reduction of the discomfort, epigastric pain and the pain 
in the right upper quadrant; normalizing of the appetite; patients 
become active and vigorous. Patients who received placebo, subjec-
tively felt slightly better, but a positive trend was almost absent. Eight 
of 14 patients had no positive changes during the first 3 days. The 
average period of elimination of toxic hepatopathy using Cytaphat 
is 2.8 days, Essentiale – 7.2 days, and placebo – 10.6 days. One 
patient withdrew from the research (female, 58 years old, without the 
 formation of cardiac anomaly) left because of the evolved tachycardia 
(120 beats/min) after the second infusion of the examined drug. The 
injection of the drug was discontinued. This led to the normalization 
of the patient’s state in 30 minutes. Cytaphat’s effect and Essentiale’s 
effect on biochemical parameters (AST, ALT, and bilirubin) is differ-
ent from effect of the placebo when employed to patients with acute 
toxic hepatitis. Antioxidant effect of Cytaphat is comparable with 
the effect of such as Essentiale.
Conclusion: The efficiency of the drug is considered to be very high; 
normalization of the state took less time compared with standard 
treatment, significant betterment is reached immediately after the 
first injection. Preliminary results give us a hope, that Cytaphat can 
become a first domestic cytoprotector with high efficiency.
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Introduction: The interplay between uptake and efflux transporters 
determines hepatic concentrations of drugs. Gd-BOPTA is a contrast 
agent used in liver magnetic resonance (MR) imaging that enters 
into human hepatocytes through OATP and exit unchanged into 
bile through MRP2. Rifampicin (RIF) is transported by the same 
membrane proteins and may compete with Gd-BOPTA for hepatic 
uptake. The aim of the study was then to elucidate the acute cel-
lular interactions between Gd-BOPTA and RIF in perfused rat liver 
preparations.
Patients (or Materials) and Methods: Normal and rats lacking the 
canalicular transporter Mrp2 were used to prepare the perfused rat 
livers. We perfused livers with 153Gd-DTPA and 153Gd-BOPTA and 
hepatic concentrations were measured using a gamma scintillation 
probe. After RIF perfusion, hepatic concentrations and bile excretion 
rates were measured using high-performance liquid chromatography.
Results: RIF perfusion greatly decreased bile flow. RIF vascular clear-
ance was maximal at time 50 minutes and decreased thereafter until time 
75 minutes. The hepatic concentrations steadily increased until the end 
of RIF perfusion. During the rinse period, an efflux of RIF from hepato-
cytes back to the systemic circulation was observed. RIF hepatic concen-
trations were higher in rats lacking Mrp2. When RIF was coperfused 
with Gd-BOPTA, the uptake index of Gd-BOPTA significantly decreased 
with increasing concentrations of perfused RIF. No effect of Gd-BOPTA 
perfused at 200 μ M was evidenced on 100 μ M RIF transport.
Conclusion: Drug–drug interactions through transporters deter-
mine the cellular concentrations of Gd-BOPTA and rifampicin. 
Furthermore, cellular concentrations regulate the Oatp-Mrp2 inter-
play by modulating transport through membranes.
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